| Place of Origin: | China |
|---|---|
| Brand Name: | ChineseHormone |
| Certification: | GMP, ISO 9001, USP |
| Model Number: | CAS 354812-41-2 |
| Minimum Order Quantity: | Free samples Available |
| Price: | negotiated |
| Packaging Details: | as your required |
| Delivery Time: | 3-7 working days |
| Payment Terms: | Western Union, MoneyGram, T/T, Bitcoin |
| Supply Ability: | 500-1000 kg / month |
| MW: | 401.431 | MF: | C21H24FN3O4 |
|---|---|---|---|
| Appearance: | Pale Yellow Powder | Biological Half-life: | 12.1 Hours |
| Trade Names: | Avelox Vigamox, Moxeza (eye Drops) | Routes Of Administration: | Oral, IV, Local (eyedrops) |
| Email: | Tonyraws810@gmail.com | Whatsapp: | 86-15871352379 |
| Wickr: | Tonyraws | ||
| High Light: | legal oral steroids,anabolic muscle building |
||
Moxifloxacin Fluoroquinolone Antibacterial Pale Yellow Powder CAS 354812-41-2
Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand namesAvelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion.
Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiellaspecies), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria.
It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria andanaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a "respiratory quinolone
Medical uses
Moxifloxacin is used to treat a number of infections, including: respiratory tract infections, cellulitis,anthrax, intraabdominal infections, endocarditis, meningitis, and tuberculosis.
The initial approval by the FDA (December 1999) encompassed these indications:
The European Union requires that moxifloxacin only be prescribed when other antibiotics that have been initially recommended for treatment cannot be used or have failed.
No uses within the pediatric population for oral and intravenous moxifloxacin have been approved. A significant number of drugs found within this class, including moxifloxacin, are not licensed by the FDA for use in children due to the risk of permanent injury to the musculoskeletal system.
In ophthalmology, moxifloxacin is approved for the treatment of conjunctival infections caused by susceptible bacteria.
|
Trade names |
Avelox,Vigamox, Moxeza (eye drops) |
|
CAS Number |
354812-41-2 |
|
Formula |
C21H24FN3O4 |
|
Molar mass |
401.431 g/mol |
|
Biological half-life |
12.1 hours |
|
Bioavailability |
86% |
|
Protein binding |
47% |
|
Routes of administration |
Oral, IV, local (eyedrops) |
Any needs, please contact me
Email: tonyraws810@gmail.com
Whatsapp: 86-15871352379
Wickr: tonyraws
